TSXV:CLAS.H - Post by User
Comment by
Captainblkon Jan 14, 2020 11:30am
![](https://assets.stockhouse.com/kentico-cms/0342-00/images/Sprite.svg#id_Post_Views_Icon)
28 Views
Post# 30551058
RE:Key market Competitor
RE:Key market Competitorthx for the insight. If you had to guess, what would that number look like to you?
MyKnight wrote: Here 's the list of the competition to Kaly with GVHD.
So Kaly has something they need if they want to continue in the GVHD field.
Just look at the Market Cap of each of them, and tell me if you be the CEO of any of them how much would you pay for world wide Rights?
Key Market Competitors: Global Graft-Versus-Host Disease (GVHD) Market
Sanofi (France), Novartis AG (Switzerland), Neovii Biotech GmbH (Germany), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Soligenix, Inc. (US), Mesoblast Ltd. (Australia), Johnson & Johnson Services, Inc. (US), Mallinckrodft (US), ElsaLys Biotech SA (France), Incyte Corporation (US), Kiadis Pharma (Netherlands) and few among others.